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ATruncation of the Human Immunodeficiency Virus-Type-2 Envelope Glycoprotein Allows
Efficient Pseudotyping of Murine Leukemia Virus Retroviral Vector Particles
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The incorporation of human immunodeficiency virus-type-2 (HIV-2) envelope glycoprotein into murine leukemia virus
(MuLV) particles was studied in a transient transfection packaging cell system. We observed that wild-type HIV-2 envelope
protein or a frameshift mutant with 187 unrelated carboxyl-terminal residues did not allow the formation of infectious
retroviral particles. In view of recent findings that an HIV-1 envelope protein variant with a shortened cytoplasmic domain was
incorporated into MuLV particles, we constructed carboxyl-terminal truncations of the HIV-2 envelope protein. An envelope
variant with 18 cytoplasmic amino acids formed only very few viral pseudotypes. The further removal of an additional 11
amino acids allowed the efficient pseudotyping of MuLV particles. As with the HIV-1 envelope protein, an HIV-2 envelope
variant with 7 cytoplasmic amino acids was incorporated into functional MuLV particles. The pseudotyped vectors obtained
are able to infect human CD4/CXCR4-expressing cells. Cell lines expressing human CD4 and other coreceptors could not be
infected. This retroviral vector will prove useful for the study of HIV infection events mediated by the HIV-2 envelope
glycoproteins, as well as for the targeting of CD41 cells in the context of gene therapy of AIDS. © 1999 Academic Press
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The host range of retroviruses (i.e., the specificity of
he infected host cells) is determined by the viral enve-
ope glycoproteins and by the receptors expressed by
arget cells. Infection is initiated by the interaction of the
nvelope protein with an appropriate receptor molecule
n the surface of the target cell (Hunter and Swanstrom,
990). For example, HIV selectively infects CD4-express-
ng human cells.
The retroviral envelope glycoproteins (Env) are synthe-
ized as a precursor polypeptide, which is cleaved by a
ellular protease to yield the surface glycoprotein (SU)
nd the transmembrane protein (TM) of the mature Env
rotein complex. The SU–TM heterodimer is held to-
ether by noncovalent interactions or, in the case of
uLV Env, by disulfide bonds. Envelope glycoproteins
re efficiently incorporated into budding virions by a still
nknown mechanism. In the absence of Env, noninfec-
ious viral core particles are formed (Hunter and Swan-
trom, 1990).
Envelope glycoprotein uptake by budding virions is a
elective process, since cellular proteins are mostly ex-
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70luded. High expression of surface proteins, however,
an lead to incorporation of cellular proteins into viral
articles (Suomalainen and Garoff, 1994). The incorpora-
ion of heterologous viral envelope proteins and their
ssociation with core particles into viral pseudotype vi-
uses indicate that the mechanism of assembly is not
erfectly specific. It has been shown that MuLV core
articles can be pseudotyped, i.e., with envelope pro-
eins of simian sarcoma-associated virus (Takeuchi et
l., 1994), feline leukemia virus subgroup B (Porter et al.,
996), feline endogenous virus RD114 (Cosset et al.,
995), vesicular stomatitis virus (VSV) G-protein (Burns et
l., 1993), simian immunodeficiency virus (SIV) (Indrac-
olo et al., 1998), and human immunodeficiency virus
IV-1 (Schnierle et al., 1997; Mammano et al., 1997).
The extent of pseudotype formation, however, is re-
tricted. Incorporation of the HIV-1 envelope protein into
uLV particles was only achieved with a variant HIV-1
nv gene encoding the surface glycoprotein gp120-SU
nd a carboxyl-terminally truncated TM protein, with only
cytoplasmic amino acids. The wild-type HIV Env com-
rises an exceptionally large cytoplasmic domain of
bout 150 amino acids. The cytoplasmic domains of
ther retroviral TM proteins generally have a size of
2–38 amino acids. Since the cytoplasmic residues are
ocated in the interior of the virion, it is conceivable that
he long cytoplasmic domain of the HIV-1-derived TM
rotein cannot be accommodated by the MuLV core and
hus interferes with particle formation.
The formation of pseudotypes of MuLV particles with
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71HIV-2/MuLV PSEUDOTYPEShe SIV envelope protein does not support this hypothe-
is. The wild-type (881 aa) and a truncated (734 aa)
IVmac envelope protein were incorporated with the
ame efficiency into MuLV particles and resulted in the
eneration of infectious retroviral vectors. These findings
rgue against steric reasons for the failure of envelope
ncorporation and might suggest specific sequence re-
uirements (Indraccolo et al., 1998).
Nucleotide sequence alignment shows that HIV-2 is
nly distantly related to HIV-1. It is more closely related to
he primate retroviruses SIVmac and SIVsm (Chakrabarti
t al., 1987). To study the ability of HIV-2 envelope pro-
eins to be incorporated into MuLV particles, we per-
ormed a carboxyl-terminal truncation analysis of the
nvelope protein of the cytopathic HIV-2 strain ISY. The
nv constructs were tested for retroviral vector transfer in
transient 293T cell-based packaging system (Pear et
l., 1993). The wild-type HIV-2 Env and a carboxyl-termi-
al extension variant were not incorporated into MuLV
articles. A naturally occurring variant of HIV-2 Env with
8 cytoplasmic amino acids was only inefficiently incor-
orated into infectious pseudotype particles. Similar to
IV-1 Env, we observed that a variant of the HIV-2 Env
ith only 7 cytoplasmic amino acids was able to form
seudotype vectors and infected human CD4/CXCR4-
xpressing cells.
The formation of viral pseudotypes changed the viral
ost range of MuLV. This new HIV-2/MuLV pseudotype
ector could efficiently transfer MLV-based vectors to
uman CD41 cells and makes it a good candidate for in
ivo somatic gene therapy and anti-HIV gene therapy.
RESULTS
onstruction of cytoplasmically truncated variants of
he HIV-2 envelope gene
We constructed the cytomegalovirus (CMV) promoter-
riven expression constructs with variants of the HIV-2
nvelope gene of the subtype A strain ISY (Franchini et
l., 1989). As described in detail under Materials and
ethods, we introduced two stop codons into the HIV-2
nvelope gene. Variant Tr710 which carries a stop codon
t position 711 generated an envelope protein with 18
ytoplasmic amino acids. This truncation can also be
ound in naturally occurring truncations of HIV-2 isolates
Kong et al., 1988). It results in enhanced fusion activity of
he envelope protein (Mulligan et al., 1992). Another stop
odon was introduced at amino acid 700 to generate
ariant Tr699 which contains 7 cytoplasmic amino acids.
he insertion of one nucleotide at position 2123 intro-
uced a frameshift in the cytoplasmic domain (Fr708)
nd resulted in a further extension of the cytoplasmic
omain to 177 amino acids unrelated to HIV 2. Figure 1
ives a schematic overview of the HIV-2 envelope vari-
nts. pharacterization of the HIV-2 envelope glycoproteins
In initial experiments, we tested the functionality of the
IV-2 envelope constructs. The expression constructs
ere transfected into the envelope-deficient MuLV-
ased packaging cell line Anjou65 (Pear et al., 1993).
fter 2 days, Western blot analysis was performed to
nvestigate the expression of HIV-2 envelope proteins.
he precursor (gp160) and the processed surface enve-
ope glycoprotein (gp120-SU) were assayed with a pa-
ient serum which detects only HIV-2 in cell lysates of
njou65 cells transfected with the wild-type HIV-2 enve-
ope gene (Fig. 2, lane 1). The frameshift mutant Fr708
nd the two truncations could only be detected as un-
leaved precursor proteins (Fig. 2, lanes 2–4). As ex-
ected, transfection of the truncation mutants resulted in
maller precursor proteins and the frameshift mutant on
he other hand migrated slightly slower than the wild-
ype protein.
Functional envelope glycoprotein must be integrated
nto the cell membrane to become incorporated into
udding viral particles. Surface expression and fusion
ctivity were determined by cocultivation of transfected
njou65 cells with HeLa-CD4 (Chesebro et al., 1990)
ells to examine syncytia formation. Syncytia are pre-
umably formed through the association of the SU enve-
ope glycoprotein encoded by the HIV-2 envelope ex-
ression plasmids, on the surface of the packaging cell
ine and the CD4 receptors present on the surface of
eLa-CD4 cells. All HIV-2 envelope variants and the
IV-1 envelope were able to form syncytia with CD4-
xpressing cells (Figs. 3A–3D and 3F), verifying a surface
xpression of the proteins. The sizes of the syncytia of
he longer HIV-2 env constructs, wild-type and frameshift,
ere slightly larger (Figs. 3A and 3B) than syncytia
ormed by the two truncation mutants (Figs. 3C and 3D).
o syncytia were formed when untransfected Anjou65
ells were cocultivated with HeLa-CD4 cells (data not
hown). Anjou65 cells expressing the amphotropic MuLV
nvelope protein did not form syncytia with CD4-ex-
ressing HeLa cells (Fig. 3E).
The data show that all HIV-2 envelope proteins were
unctionally expressed on the surface of MuLV gag-pol-
xpressing packaging cell lines.
nfectivity of pseudotyped MuLV capsid particles
ncorporating truncated HIV-2 envelope glycoproteins
We attempted to create pseudotyped retroviral vector
articles comprising the MuLV capsid and the HIV-2
nvelope glycoproteins. For this purpose we modified
he cell line Anjou65 (Pear et al., 1993) which produces
uLV capsid particles, but no envelope proteins. An-
ou65 cells were transduced with amphotropic retroviral
ector particles from FLYA-LacZ cells (Cosset et al.,
995), containing the MFGnlslacZ vector. The derived
ackaging cell line, Anjou65-LacZ, expressed the retro-
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72 HO¨HNE ET AL.iral vector MFGnlsLacZ in addition to MuLV gag-pol.
pon transfection of a suitable envelope gene, infectious
etroviral particles are formed and transfer of the lacZ
ene can be monitored by in situ X-gal staining.
Anjou65-LacZ cells were transfected with the HIV-2
nvelope expression constructs. Supernatants of Anjou-
acZ cells expressing the viral envelope glycoproteins
ere collected 2 days after transfection. One milliliter of
upernatant was used for the infection of the human
D4-expressing cells (HeLa-CD41). Upon staining with
FIG. 1. Envelope glycoproteins derived from the env genes of HIV-1
lycoproteins of HIV-2 consisting of a total of 848 amino acids (strain ISY
f the HIV-2 envelope gene with stop codons at amino acids 700 and 711
residue at position 2123. Plasmid pCMX-HIV-1 Tr712 encodes a trunc
mino acid position 712. The coding region of the MuLV-derived envel-gal of the cells exposed to the cell supernatants, blue folonies (indicative of MFGnlslacZ gene expression)
ere detected, indicating functional gene transfer. Titers
ere determined by counting the blue colonies (Table 1).
upernatants from Tr699-transfected Anjou65-LacZ cells
ave rise to 640 blue colonies per milliliter of superna-
ant. Truncated Tr710 had a 200-fold lower viral titer (3
lue cells per milliliter). No blue colonies were observed
ith wild-type and frameshift (Fr708) HIV-2 Env con-
tructs. Despite being expressed on the surface of the
ackaging cell line, the longer HIV-2 constructs did not
and MuLV. Plasmid pCMX-HIV-2 wt encodes the wild-type envelope
hini et al., 1989). Plasmids HIV-2 Tr699 and T710 are truncated variants
ctively. Construct Fr708 encodes a frameshift variant due to an inserted
ariant of the HIV-1 TM protein due to the insertion of a stop codon at
oteins is shown for comparison., HIV-2,
; Franc
, respe
ated vorm infectious MuLV particles and were not able to
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73HIV-2/MuLV PSEUDOTYPESransfer the marker gene efficiently into human CD41
ells. Only the HIV-2 envelope protein with 7 cytoplasmic
mino acids formed infectious pseudotype particles and
his was similar to previous observations with the HIV-1
nvelope protein (Schnierle et al., 1997; Mammano et al.,
997). The titers obtained with the HIV-2 variant Tr699
ere compared with viral titers obtained with the HIV-1
nvelope protein or the amphotropic MuLV envelope
rotein, in the same transient transfection system. Data
rovided in Table 1 illustrate that HIV-2 envelope variant
r699 and HIV-1 variant Tr712 gave rise to similar
mounts of viral pseudotype particles. The titer of these
atter variants when compared to the homologous am-
hotropic MuLV envelope protein showed an approxi-
ate 10-fold decrease in viral titer.
oreceptor usage of HIV-2/MuLV pseudotype vector
articles
HIV infection of a cell requires, in addition to the
rimary receptor CD4, the presence of a coreceptor. The
IV coreceptors belong to the family of chemokine re-
eptors and the type of chemokine receptor used by the
irus is indicative of the viral subtype. The host range of
he truncated HIV-2 envelope protein Tr699 was tested
y the gene-transfer ability of the pseudotyped vector
articles on mouse cell lines expressing different sets of
IV receptors and coreceptors.
Pseudotype retroviral vector particles were produced
y transfection of Anjou65-LacZ cells with the envelope
xpression constructs. After incubation with viral super-
atants, target cells were stained after 2 days for beta-
al expression. All cell lines could be transduced with
mphotropic retroviral vectors (Fig. 4). As expected for a
FIG. 2. Detection of HIV-2 Env expression in transfected Anjou65 c
estern blot analysis was performed with antibodies directed against
onors and horseradish peroxidase-coupled goat anti-human antibody
n the figure.ubtype A isolate of HIV-2, gene transfer was only de- tected in CD4- and CXCR4-expressing cells (Unutmaz et
l., 1998) (Fig. 4). The same results were obtained with
he HIV-1 pseudotype vectors and the HIV-2 Tr710 con-
tructs (data not shown). Isolate BH10, from which the
nvelope gene was derived, is known to use CD4 and
XCR4 receptors for cell entry. Expression of CD4 recep-
or alone or in combination with the chemokine receptors
CR5 and CCR3 was not sufficient for gene transfer.
rom these data we conclude that truncation of most of
he cytoplasmic domain of the HIV-1 or -2 envelope
rotein and pseudotyping with a heterologous core do
ot change coreceptor usage, i.e., viral host range.
DISCUSSION
We describe the construction of carboxyl-terminal
runcations in the HIV-2 envelope protein and the forma-
ion of HIV-2/MuLV pseudotype particles. The derived
runcated envelope proteins were transported to the cell
urface and were membrane fusion competent. Process-
ng into SU and TM domains was greatly reduced in the
odified forms of the HIV-2 envelope glycoprotein and
as below detection level by Western blot analysis. Ret-
oviral HIV-2/MuLV pseudotype vectors with specificity
or human CD4/CXCR4-expressing cells were efficiently
enerated with the shortest variant of the HIV-2 envelope
rotein which had 7 cytoplasmic amino acids.
seudotype formation with a slightly longer HIV-2 enve-
ope protein Tr710 (11 additional amino acids) was sig-
ificantly reduced.
Wild-type HIV-2 env gene products or a randomly ex-
ended frameshift mutant did not form infectious
seudotype particles. This is consistent with previous
tudies in which MuLV (HIV-1 ENV) pseudotype forma-
tes. Nontransfected Anjou65 cells were used as a negative control.
-2 envelope glycoprotein gp160 derived from serum of HIV-2-infected
the ECL system (Amersham) for detection. Loading was as indicatedell lysa
the HIV
usingion could not be demonstrated (Wilson et al., 1989;
H
w
E
74 HO¨HNE ET AL.FIG. 3. Demonstration of the functional expression of the HIV-2 surface glycoproteins by syncytia formation with CD4 receptor expressing
eLa-CD4 cells. Transiently transfected Anjou65-LacZ cells were overlaid with an equal amount of CD4 receptor-expressing HeLa cells. Cocultivation
as continued for 20 h before they were photographed. (A) Anjou65-LacZ/HIV-2 ENV wt; (B) Anjou65-LacZ/HIV-2 ENV Fr708; (C) Anjou65-LacZ/HIV-2
NV Tr710; (D) Anjou65-LacZ/HIV-2 ENV Tr699; (E) Anjou65-LacZ/amphotropic ENV; and (F) Anjou65-LacZ/HIV-1 ENV Tr712.
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75HIV-2/MuLV PSEUDOTYPESchnierle et al., 1997; Mammano et al., 1997). Since HIV
nvelopes have exceptionally long cytoplasmic domains
150 amino acids) and the MuLV envelope carries only 32
ytoplasmic amino acids, it is conceivable that the long
ytoplasmic domain of the HIV-1- and HIV-2-derived TM
roteins cannot be accommodated by the MuLV core
nd interferes with particle formation. Similar observa-
ions were made recently with lentiviruses (Henriksson
nd Bosch, 1998). The human CD4 receptor could only
e incorporated into lentiviral particles, when the natural
nteracting partner p56lck was absent. A truncated ver-
ion of CD4 lacking the cytoplasmic carboxyl terminus
as unable to bind p56lck and was incorporated into
IV-like particles, whereas wild-type CD4 was not (Hen-
iksson and Bosch, 1998). On the contrary, both the
ild-type and a carboxyl-terminal truncation of the SIV-
ac239 envelope glycoprotein generated MuLV
seudotypes with similar titers. Due to the sequence
omology between SIV and HIV-2, the conflicting results
ould suggest a different secondary structure for the SIV
nvelope glycoprotein, to be compatible with the MuLV
ore.
The naturally occurring truncation Tr710 is also ineffi-
iently incorporated into viral particles. The truncation is
requently observed with isolates of HIV-2 and SIV
Chakrabarti et al., 1989; Hirsch et al., 1989; Naidu et al.,
988) and these glycoproteins exhibit enhanced mem-
rane fusion activity. Truncated Tr710 contains the Tyr-
ased motif YXXØ (Y, Tyr; X, any amino acid; Ø, amino
cids with a bulky hydrophobic side chain like Leu, Ile,
he, Val, or Met), which is involved in the trafficking and
ndocytosis of membrane proteins via clathrin-coated
its associated with AP-1 and AP-2 adaptor complexes
TABLE 1
Titers of Pseudotype Vectors Determined by X-Gal Staining
Envelope Titer (in IU/ml on HeLaCD4)
HIV-2 ENV wt #1
HIV-2-ENV Fr 708 #1
HIV-2 ENV Tr 710 3
HIV-2 ENV Tr 699 6.4 3 102
HIV-1 ENV Tr 712 2.7 3 102
Amphotropic ENV 6.7 3 103
Note. Anjou65-LacZ cells were transfected with 20 mg envelope
xpression plasmid using a standard calcium phosphate precipitation
echnique. HeLa-CD4 cells were seeded in 24-multiwell plates at a
ensity of 4 3 104 cells per well. Prior to infection the cells were
ncubated in cell medium overnight. Infections were carried out by 3-h
ncubation of the target cells with 1 ml of supernatants of transfected
njou65-LacZ cells, containing retroviral particles. Infections with am-
hotropic retroviral vectors were carried out in the presence of 8 mg/ml
olybrene. The cells were stained for b-gal expression 2 days after
nfection (Schnierle et al., 1997). Viral titers were determined by count-
ng blue cells. The titers are expressed in infectious units per milliliters
IU/ml).Trowbridge et al., 1993). Recently, it was shown that Tusion proteins of the extracellular part of the CD8 re-
eptor and the membrane-proximal TM region of HIV-1
nd SIV (amino acids 707–726 for HIV-1 or amino acid
16–733 for SIV) were capable of interacting with the
lathrin-associated adaptor complex. The interaction de-
ended on the tyrosine residue of the YXXØ motif. This
nteraction was not observed with the full-length TM
egions, implying that the membrane-proximal Tyr-based
otif is not the only sequence in the long TM region of
entiviruses involved in recruitment of the clathrin-asso-
iated adaptor complex (Berlioz-Torrent et al., 1999). The
top codons of the shortest HIV-2 variant Tr699 and the
IV-1 variant Tr712 are located in the Tyr-based motif, so
hat the Tyr of the YXXØ motif encompasses the last
mino acid of these proteins. It is tempting to speculate
hat deletion of the Tyr-based motif allows increased
ncorporation of lentiviral envelope proteins into MuLV
articles. The mechanism could involve either the in-
reased surface expression of the envelope proteins due
o the elimination of the Tyr-based motif or a decreased
ncorporation of the longer variant Tyr 710 due to the
teric hindrance through the presence of the clathrin-
oated pits associated with AP-1 and AP-2 adaptor com-
lexes.
Several important applications of the MuLV (HIV-2)
ectors characterized in this paper can be envisaged.
he delivery of therapeutic genes to CD4-expressing
ells and the study of the molecular events of HIV infec-
ion are two possibilities. The primary target cells of HIV
re CD41 lymphocytes and several gene therapy strat-
gies have been described which aim to introduce pro-
ective genes into these cells which interfere with infec-
ion or the viral replication process. It is conceivable that
n vivo or ex vivo transduction of CD41 lymphocytes with
xpression constructs that counteract HIV replication
ight help to reduce the virus load in the peripheral
lood and/or lymph nodes of infected patients. An ad-
antage in the use of HIV-2 pseudotyped vectors in gene
herapy lies in the absence of preexisting antibodies in
IDS patients, since HIV-1 is the most dominant strain
ound in AIDS patients. Additional useful applications
an be envisaged.
MuLV (HIV-1 and HIV-2) pseudotypes will also be use-
ul as a safe and rapid assay system for the analysis of
olecules that affect HIV-1 entry and permit the devel-
pment of drugs that interfere with the HIV-1 infection
rocess.
MATERIALS AND METHODS
lasmids
The amphotropic MuLV envelope expression construct
HIT 111 was obtained from A. Kingsman (Soneoka et al.,
995). The HIV-2 expression construct pSVL HIV-isy-env
as obtained from M. Mulligan (Franchini et al., 1989).
he env coding sequences were excised as a XhoI–SalI
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77HIV-2/MuLV PSEUDOTYPESragment and cloned into the expression vector
CMX-P1 (Pfitzner et al., 1995). The expression vector
arries the env sequences downstream of a human CMV
romoter. The point mutations in the env coding se-
uences were introduced using the Quick Change site-
irected mutagenesis kit (Stratagene, Heidelberg, Ger-
any) according to the manufacturer’s protocol. Variant
r699 was constructed by exchanging sequence AGG of
odon 700 with premature termination codon TGA. Vari-
nt Tr710 had a stop codon (TAA) in place of codon 711
CAA). Frameshift variant Fr708 was introduced by inser-
ion of a T at position nt 2123 and an additional TAA
odon at amino acid 711. The variants were sequenced
ver the entire coding region.
ell culture and transfections
HeLa-CD41 cells (ADP047; Chesebro et al., 1990),
IH3T3 cells, and Anjou65 cells (Pear et al., 1993) were
rown in Dulbecco’s modified Eagle’s Medium (DMEM;
IBCO/BRL, Eggenstein, Germany) supplemented with
0% fetal calf serum (FCS; GIBCO/BRL).
A day before transfection, Anjou65 cells were seeded
t a density of 1 3 106 cells in a 10-cm tissue culture
late. The cells were transfected with 10–20 mg expres-
ion plasmid using a standard calcium phosphate pre-
ipitation technique.
Anjou65-LacZ cells were obtained after transduction
f Anjou65 cells in the presence of 8 mg/ml polybrene
ith supernatants of the amphotropic packaging cell line
LYA-LacZ (Cosset et al., 1995), transferring the MF-
nlslacZ vector. After three repetitions of the transduc-
ion procedure, all cells were positive after X-gal stain-
ng.
iral infection and determination of titers
Adherent target cells were seeded in 24-multiwell
lates at a density of 4 3 104 cells per well. Prior to
nfection the cells were incubated in cell medium over-
ight. Infections were carried out by 3 h incubation of the
arget cells with 1 ml of supernatants containing retrovi-
al particles. Contaminating cells in the viral superna-
ants had been previously removed by passage through
.45-mm filters. Infections with amphotropic retroviral
ectors were carried out in the presence of 8 mg/ml
olybrene. The cells were stained for b-gal expression 2
ays after infection (Schnierle et al., 1997). Viral titers
ere determined as described (Schnierle et al., 1997).
he titers are expressed in infectious units per milliliter
IU/ml).
estern blot analysis
Cell lysates were obtained and Western blot analyses
ere performed as described previously (Schnierle et al.,
996). Western blot analysis was performed with patient
erum from HIV-2-infected individuals (gift of Professor Iu¨rtler, Mu¨nich, Germany) and horseradish peroxidase-
oupled goat anti-human IgA 1 IgG 1 IgM antibodies
Dianova, Hamburg, Germany), using the enhanced
hemiluminescence Western blot detection kit (Amer-
ham, Braunschweig, Germany).
embrane fusion capacity of the HIV-1 envelope
rotein
Anjou65 packaging cells were transiently transfected
ith the HIV-2 expression constructs and were cultured
or 1 day. The cells were overlaid with an equal amount
f CD4 receptor-expressing cells. Cocultivation was con-
inued for 20 h, after which the cells were photographed.
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